Brian Rini
机构: Vanderbilt University Medical Center
每年引用次数
引用次数
引用: 82,216
H-指数: 127
I10-指数 : 564
出版物: 1,236
Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.
Thomas Powles , Laurence Albiges , Katriina Johanna Jalkanen , Guillermo De Velasco
Journal of Clinical Oncology 42 ( 4_suppl) 361 -361
4
2024
Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.
Renee Maria Saliby , Tejas Jammihal , Chris Labaki , Wanling Xie
Journal of Clinical Oncology 40 ( 16_suppl) 4531 -4531
4
2022
A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).
Elizabeth R Plimack , Hans J Hammers , Toni K Choueiri , Brian I Rini
Journal of Clinical Oncology 39 ( 15_suppl) TPS4594 -TPS4594
4
2021
Outcomes of patients who progressed while receiving avelumab+ axitinib (A+ Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.
Laurence Albiges , Martin H Voss , Brian I Rini , Gwenaelle Gravis
Journal of Clinical Oncology 39 ( 15_suppl) 4514 -4514
4
2021
Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study
Matthew D Tucker , Martin H Voss , Toni K Choueiri , Mehmet Asim Bilen
Clin Oncol 39 ( 4549) 10.1200 -10.1200
3
2021
Plain language summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma
Brian I Rini , Michael B Atkins , Toni K Choueiri , Rosemary E Teresi
Future Oncology 19 ( 40) 2623 -2629
2
2023
Overall survival (OS) in meteor, a randomised phase III trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC)
Paul Mainwaring , Thomas Powles , Bernard J Escudier , Nizar M Tannir
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13 109 -109
2
2017
METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
Thomas Powles , Bernard Escudier , Paul N Mainwaring , Brian I Rini
BJU INTERNATIONAL 116 19 -19
2
2015
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma
Toni K Choueiri , Amber C Donahue , David A Braun , Brian I Rini
Cancer Discovery 14 ( 3) 406 -423
1
2024
LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma
Toni K Choueiri , Thomas Powles , Martin H Voss , Elizabeth R Plimack
Future Oncology 19 ( 40) 2631 -2640
1
2023
Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
Toni K Choueiri , Elizabeth R Plimack , Thomas Powles , Martin H Voss
JOURNAL OF CLINICAL ONCOLOGY 40 ( 6)
1
2022
CheckMate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (aRCC) with sarcomatoid features (sRCC)
Marc-Oliver Grimm , David F Mcdermott , Toni K Choueiri , Robert J Motzer
Oncology Research and Treatment 43 70 -71
1
2020
Association Between Depth of Response (DepOR) and Overall Survival (OS): Exploratory Analysis of Nivolumab plus Ipilimumab (N plus I) vs Sunitinib (S) in Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) in Checkmate 214
Viktor Gruenwald , Toni K Choueiri , Brian I Rini , Thomas Powles
Oncology Research and Treatment 43 74 -75
1
2020
Uncommon tumors of the kidney
Guillermo De Velasco , Sabina Signoretti , Brian I Rini , Toni K Choueiri
Textbook of Uncommon Cancer 19 -40
1
2017
JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
Toni K Choueiri , Brian I Rini , Thomas Cosgriff , Hideaki Miyake
BJU INTERNATIONAL 118 29 -30
1
2016
Avelumab+ axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
Robert J Motzer , Konstantin Penkov , Hirotsugu Uemura , Matthew T Campbell
Journal of Clinical Oncology 42 ( 16_suppl) 4508 -4508
2024
Development of a patient-centered health-related quality of life (HRQOL) measure for metastatic renal cell carcinoma (mRCC): A three-phase study.
Cristiane Decat Bergerot , Daniela V Castro , Paulo Gustavo Bergerot , Benjamin D Mercier
Journal of Clinical Oncology 42 ( 4_suppl) 365 -365
2024
Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D.
Cristiane Decat Bergerot , Benjamin D Mercier , Daniela V Castro , Paulo Gustavo Bergerot
Journal of Clinical Oncology 41 ( 16_suppl) 4540 -4540
2023
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K Choueiri , Amber C Donahue , Brian I Rini , Thomas Powles
JOURNAL OF CLINICAL ONCOLOGY 39 ( 15)
2021
Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab+ axitinib (A+ Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
Toni K Choueiri , Amber C Donahue , Brian I Rini , Thomas Powles
Journal of Clinical Oncology 39 ( 15_suppl) 4547 -4547
2021